Navigation Links
CryoLife Reports Record Revenues for the Second Quarter and First Six Months of 2011
Date:7/28/2011

uded approximately $2.6 million in costs related to the Company's acquisition of Cardiogenesis and other business development activities.  General, administrative, and marketing expenses for the first six months of 2010 included approximately $550,000 in costs related to business development activities.

Research and development expenses were $1.6 million and $1.2 million for the second quarters of 2011 and 2010, respectively.  Research and development expenses were $3.4 million and $2.5 million for the first six months of 2011 and 2010, respectively.  Research and development spending in 2011 was primarily focused on PerClot, SynerGraft® tissues and products, BioFoam® Surgical Matrix, and BioGlue.  

Other income was $28,000 for the second quarter of 2011 compared to $215,000 for the second quarter of 2010.  Other income was $116,000 for the first six months of 2011 compared to $865,000 for the first six months of 2010.  Other income for the first six months of 2010 consisted primarily of a $1.2 million gain on valuation of the derivative related to an investment in common stock.

As of June 30, 2011, the Company had $25.1 million in cash, cash equivalents, and restricted securities, compared to $40.8 million at December 31, 2010.  The decrease in cash, cash equivalents, and restricted securities is largely a result of the $21.7 million paid for the acquisition of Cardiogenesis.  Of this $25.1 million in cash, cash equivalents, and restricted securities, $1.5 million was received from the U.S. Department of Defense as advance funding for the development of BioFoam protein hydrogel technology, and $5.3 million was designated as restricted securities primarily due to a financial covenant requirement under the Company's credit agreement.  The Company used $3.5 million of its cash to fund the purchase of Senior A Preferred stock of ValveXchange in early July 2011.  The Company's net cash flow
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. CryoLife Announces Release Date and Teleconference Call Details for 2011 Second Quarter Financial Results
2. CryoLife Makes Equity Investment in ValveXchange® Inc.
3. CryoLife Announces Completion of Acquisition of Cardiogenesis
4. CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation
5. CryoLife Completes Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation
6. CryoLife Posts Record Quarterly Revenues of $30.2 Million
7. CryoLife Launches BioGlue® Surgical Adhesive in Japan
8. CryoLife Announces Release Date and Teleconference Call Details for 2011 First Quarter Financial Results
9. CryoLife Announces Expiration of Go-Shop Period Related to its Proposed Acquisition of Cardiogenesis Corporation
10. CryoLife Commences Tender Offer for All Outstanding Shares of Cardiogenesis Corporation
11. CryoLife Signs Definitive Agreement to Acquire Cardiogenesis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... N.J. , July 24, 2014 /PRNewswire/ ... CTSH ) today announced that it has ... , a non-profit organization with membership representation ... a first-of-its-kind, subscription-based platform that will transform ... companies on clinical trials. TransCelerate BioPharma Inc. ...
(Date:7/23/2014)... 2014  Varian Medical Systems (NYSE: VAR ... diluted share in the third quarter of fiscal year ... per diluted share due to an approximately $8 million ... equity investment in Augmenix, a privately-held company developing minimally ... million for the third quarter of fiscal year 2014, ...
(Date:7/23/2014)... DUBLIN , July 23, 2014 ... "Diagnostic Electrocardiograph (ECG) Market by Product, End-user & ... report to their offering. ... market is segmented into three major segments, namely, holter ... overall market was valued at $3,683 million in 2013 ...
Breaking Medicine Technology:TransCelerate Selects Cognizant to Develop a Clinical Trials Collaboration Platform 2TransCelerate Selects Cognizant to Develop a Clinical Trials Collaboration Platform 3TransCelerate Selects Cognizant to Develop a Clinical Trials Collaboration Platform 4TransCelerate Selects Cognizant to Develop a Clinical Trials Collaboration Platform 5Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 2Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 3Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 4Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 5Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 6Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 7Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 8Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 9Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 10Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 2Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 3
... Cayenne Medical, Inc., a private sports medicine device ... that effective immediately, David B. Springer will succeed James ... transitioned to Executive Chairman due to health reasons. ... President and CEO since the company,s inception in 2005, ...
... ACCESS PHARMACEUTICALS, INC. ... a biopharmaceutical company leveraging its proprietary drug-delivery platforms to ... and diabetes, reported it has been receiving ... MuGard for patients undergoing radiation and chemotherapy for various ...
Cached Medicine Technology:Cayenne Medical, Inc. Appoints David B. Springer President & CEO 2Cayenne Medical, Inc. Appoints David B. Springer President & CEO 3Access Pharmaceuticals Receives Early MuGard Prescriber Anecdotal Feedback Validating Larger Target Market Potential 2Access Pharmaceuticals Receives Early MuGard Prescriber Anecdotal Feedback Validating Larger Target Market Potential 3Access Pharmaceuticals Receives Early MuGard Prescriber Anecdotal Feedback Validating Larger Target Market Potential 4
(Date:7/24/2014)... Professional Healthcare at Home, an affiliate of ... a nurse with the company’s Pleasant Hill, CA, home health ... the 2014 Home Care & Hospice Nurse of the Year ... Hospice (NAHC). , Annually, NAHC promotes a nationwide recognition ... help choose a top home care and hospice nurse from ...
(Date:7/24/2014)... Imbue Partners is pleased ... (WOSB) by the National Women Business Owners Corporation ( ... party certifier. , Located near Boston, MA, Imbue ... to drive growth through strategic planning, organizational competencies, and ... activating options through teams, tools, and technologies for all ...
(Date:7/24/2014)... Colleen’s Dream Foundation, in partnership with Fidelity ... Medicine to fund ovarian cancer research, according to Colleen’s ... this is the second year in a row Colleen's ... Hopkins Medicine. , “One of the main goals of ... investigators at some of the top research hospitals and ...
(Date:7/23/2014)... Jose, CA (PRWEB) July 23, 2014 ... for health and beauty products do not include various ... company is now revealing skin tightening cream discounts inside ... . , The guide is now available to offer ... to find recently released products available for sale. Although ...
(Date:7/23/2014)... Men and women who are married ... insurance based on national averages. The Quotes Pros company ... to its comprehensive tool this year to help married ... , Providers that are now underwriting plans on a ... one or two clicks. The intelligent platform used to ...
Breaking Medicine News(10 mins):Health News:Professional Healthcare at Home’s Karen Schulkin Named Top 10 Finalist Representing California for 2014 Home Care & Hospice Nurse of the Year 2Health News:Professional Healthcare at Home’s Karen Schulkin Named Top 10 Finalist Representing California for 2014 Home Care & Hospice Nurse of the Year 3Health News:Imbue Partners Certified as Woman-Owned Small Business 2Health News:Colleen’s Dream Foundation Donates $10,000 to Johns Hopkins Medicine for Ovarian Cancer Research 2Health News:Colleen’s Dream Foundation Donates $10,000 to Johns Hopkins Medicine for Ovarian Cancer Research 3Health News:Skin Tightening Cream Discounts Revealed in New Cost Saving Guide at Consumer Portal 2Health News:Cheap Life Insurance Rates for Married Couples Added to Search System at Insurer Portal Online 2
... have reported that use of narcotics for chronic pain ... //ask for increasing the dose. On the other hand, ... lead to constant increase in the dosage with serious ... pain medications like morphine, methadone and oxycodone. Opioid drugs ...
... Korean scientists have been able to clone human embryos for ... with diseases or injury. The newly created stem cell lines ... systems. ,. ,This research have provided new insight into ... on them as a treatemnt. This is for the first ...
... that colonoscopy may be the favorable method to screen ... colorectal cancer, flexible sigmoidoscopy is used to detect colorectal ... with dysplasia, or cancer. Researchers had used colonoscopy to ... for women who were referred for colon-cancer screenings. ,Of ...
... infection of the lungs, says a study published in the ... of age between 2 to 49 years for a period ... pneumococcal disease, 10 persons of the same population were chosen ... of diagnosis of asthma by the emergency room, or the ...
... of colon cancer after undergoing surgery can reduce the risk ... which was presented at the annual meeting of American Society ... by about 50% for the patients who took regular aspirin ... cancer. ,Colon and rectum together form the colorectal area. ...
... Attention Deficit Hyperactivity Syndrome (ADHD) may now to treated ... interventions like applying deep pressure or putting them through ... is a condition that affects nearly 3 to 5 ... Children with ADHD are known to be impulsive, inattentive ...
Cached Medicine News:
... Random Dot Stereo Depth Perception for ... of arc) and Fine Depth,Perception. , ... (800 to 40 sec of arc), ... to 100 sec of arc), 1 ...
Our high quality therapeutic drug monitoring reagents, calibrators and controls are available for most chemistry analyzers. Reproducible and accurate results for your laboratory needs....
The Emit 2000 Phenytoin Assay is a homogeneous enzyme immunoassay for use in the quantitative analysis of phenytoin in human serum or plasma. Kits are conveniently packaged in Olympus Reagent Cartrid...
... Digoxin Assay is a homogeneous ... in the quantitative analysis of ... plasma. Kits are packaged specifically ... COBAS MIRA, COBAS MIRA S, ...
Medicine Products: